Finance

Lists
TXG:NASDAQ
10X Genomics Inc
$58.19
-1.54%
(-0.91) 1D
$57.00
-2.05% (-1.19)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TXG...
Open
$59.50
High
$59.50
Low
$56.32
Mkt. cap
7.65B
Avg. vol.
3.85M
Volume
2.13M
52-wk high
$102.81
52-wk low
$15.12
EPS
-$0.52
Beta
2.03
Shares outstanding
121.46M
No. of employees
1K
Open
$59.50
High
$59.50
Low
$56.32
Mkt. cap
7.65B
Avg. vol.
3.85M
Volume
2.13M
52-wk high
$102.81
52-wk low
$15.12
EPS
-$0.52
Beta
2.03
Shares outstanding
121.46M
No. of employees
1K
News stories
From web sources and news partners
Profile
10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics. Wikipedia
About 10X Genomics Inc
CEOSerge Saxonov
Employees1.18K
Founded2012
HeadquartersPleasanton, California, United States
SectorHealth Care
Industry-
Analyst ratings
Based on 15 analysts giving stock ratings to TXG in the past 3 months
Buy
Buy
5
Hold
10
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for TXG in the last 3 months.
Highest
Current $58.19
$110.00 (+89.04%)
Average
$74.15 (+27.43%)
Lowest
$55.00 (-5.48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mason Carrico
Stephens
Hold
Maintained
$65.00
+11.7%
11/11/2026
Casey Woodring
J.P. Morgan
Hold
Reiterated
$65.00
+11.7%
11/09/2026
Luke Sergott
Barclays
Buy
Maintained
$70.00
+20.3%
11/09/2026
Doug Schenkel
UBS
Hold
Reiterated
$61.00
+4.8%
11/09/2026
‏Avantika Dhabaria‏
Bank of America Securities
Hold
Maintained
-
-
11/06/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
$100.00
+71.9%
11/06/2026
David Westenberg
Piper Sandler
Hold
Maintained
$80.00
+37.5%
11/06/2026
Dan Leonard
RBC Capital
Hold
Maintained
$70.00
+20.3%
11/05/2026
Daniel Brennan
TD Cowen
Hold
Maintained
$55.00
-5.5%
11/06/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
$68.00
+16.9%
11/06/2026
Patrick B Donnelly
Citi
Hold
Maintained
$60.00
+3.1%
11/06/2026
Kallum Titchmarsh
Morgan Stanley
Hold
Reiterated
$70.00
+20.3%
10/13/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
$80.00
+37.5%
10/09/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/29/2026
Puneet Souda
Leerink Partners
Hold
Maintained
$90.00
+54.7%
09/29/2026
Unknown Analyst
Argus Research
Buy
Initiated
$110.00
+89%
09/28/2026
John Eade
Argus Research
Buy
Initiated
$110.00
+89%
09/25/2026
Unknown Analyst
UBS
Hold
Initiated
$68.00
+16.9%
09/08/2026
Unknown Analyst
Stephens
Buy
Reiterated
$65.00
+11.7%
08/12/2026
Tycho Peterson
Jefferies
Buy
Reiterated
$53.00
-8.9%
08/07/2026
‏Brendan Digan‏
Citi
Hold
Maintained
$50.00
-14.1%
08/07/2026
Justin Bowers
Deutsche Bank
Hold
Maintained
$23.00
-60.5%
05/08/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.03 / -$0.02
+240.30%beat
Revenue / Est. (USD)
150.67M / 148.23M
+1.64%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
166.03M
150.84M
151.04M
150.67M
Cost of goods sold
52.88M
44.66M
38.54M
37.74M
Cost of revenue
52.88M
44.66M
38.54M
37.74M
Research and development expenses
55.77M
56.85M
56.79M
52.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
73.02M
66.38M
78.66M
76.06M
Operating expense
128.79M
123.22M
135.45M
128.98M
Total operating expenses
181.67M
167.89M
173.99M
166.72M
Operating income
-15.64M
-17.05M
-22.96M
-16.06M
Other non operating income
-3.04M
-72.00K
-3.49M
-37.00K
EBT including unusual items
-15.19M
-12.85M
-18.64M
-18.48M
EBT excluding unusual items
-12.39M
-12.90M
-22.04M
-10.68M
Income tax expense
1.06M
623.00K
-714.00K
949.00K
Effective tax rate
-6.97%
-4.85%
3.83%
-5.14%
Other operating expenses
-
-
-
-
Net income
-16.25M
-13.47M
-17.93M
-19.42M
Net profit margin
-9.79%
-8.93%
-11.87%
-12.89%
Earnings per share
0.07
0.07
0.03
0.03
Interest and investment income
6.89M
5.01M
4.80M
5.02M
Interest expense
-
-
-
-
Net interest expenses
6.89M
5.01M
4.80M
5.02M
Depreciation and amortization charges
-
-
-
-
EBITDA
-5.58M
-7.09M
-13.29M
-6.55M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps